Supriya Lifescience Limited (SUPRIYA.NS)
INR 638.35
(-1.05%)
INR 638.35
(-1.05%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.05 Billion INR | -12.37% |
| 2022 | 1.2 Billion INR | 1.46% |
| 2021 | 1.19 Billion INR | -32.68% |
| 2020 | 1.76 Billion INR | -5.53% |
| 2019 | 1.87 Billion INR | 17.57% |
| 2018 | 1.59 Billion INR | -16.5% |
| 2017 | 1.9 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 1.06 Billion INR | 113.06% |
| 2024 Q1 | -8.15 Billion INR | -870.16% |
| 2023 FY | 1.05 Billion INR | -12.37% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q4 | 1.05 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 898.57 Million INR | 0.0% |
| 2022 Q4 | 1.2 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q2 | 1.09 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 1.2 Billion INR | 1.46% |
| 2021 Q2 | 1.69 Billion INR | 0.0% |
| 2021 FY | 1.19 Billion INR | -32.68% |
| 2021 Q4 | 1.19 Billion INR | 0.0% |
| 2020 Q3 | 1.31 Billion INR | 0.0% |
| 2020 FY | 1.76 Billion INR | -5.53% |
| 2020 Q4 | 1.76 Billion INR | 34.25% |
| 2019 FY | 1.87 Billion INR | 17.57% |
| 2018 FY | 1.59 Billion INR | -16.5% |
| 2017 FY | 1.9 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Biocon Limited | 307.95 Billion INR | 99.656% |
| Blue Jet Healthcare Limited | 2.13 Billion INR | 50.441% |
| Concord Biotech Limited | 1.74 Billion INR | 39.177% |
| Dishman Carbogen Amcis Limited | 39.53 Billion INR | 97.322% |
| Jubilant Ingrevia Limited | 19.94 Billion INR | 94.692% |
| Lyka Labs Limited | 884.58 Million INR | -19.683% |
| Panacea Biotec Limited | 4.02 Billion INR | 73.665% |
| Piramal Pharma Limited | 74 Billion INR | 98.569% |
| SMS Lifesciences India Limited | 1.96 Billion INR | 46.227% |
| Syngene International Limited | 18.93 Billion INR | 94.41% |
| TAKE Solutions Limited | 969.78 Million INR | -9.169% |
| Zota Health Care Limited | 1.38 Billion INR | 23.478% |